Roche Holding AG (RHHVF)
OTC
Closed
Aug 21, 2026
Day's Range
451.3052 wk Range
314.15Overview - RHHVF - Roche Holding AG
Key Statistics
Valuation
Enterprise Value
500.48B
P/E (Trailing)
‪24.39‬
P/E (Forward)
‪17.60‬
PEG Ratio
‪17.60‬
Price / Sales (TTM)
‪5.93‬
Price / Book
‪9.25‬
EV / EBITDA
‪16.73‬
Profitability
Profit Margin
‪19.60%‬
Operating Margin
‪36.20%‬
Return on Assets
‪13.50%‬
Return on Equity
‪38.10%‬
Ownership
Shares Outstanding
796.76M
Float
654.08M
Held by Insiders
‪0.00%‬
Held by Institutions
‪44.00%‬
Price stats
Beta
‪0.34‬
50-Day Avg
‪426.29‬
200-Day Avg
‪416.34‬
Dividends
Payout Ratio
‪63.93%‬
Frequency
Annual
Analyst Consensus
1 analysts
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - RHHVF - Roche Holding AG
Peers - RHHVF - Roche Holding AG
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on OTC.
Profile Summary - RHHVF - Roche Holding AG
About
Roche Holding AG is a Swiss biopharmaceutical and diagnostics company headquartered in Basel, Switzerland. The company develops, manufactures, and markets innovative medicines and diagnostic solutions worldwide, with a strong focus on oncology therapies derived from its integration with Genentech. Its bestselling…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
